文献速递肿瘤 PET/CT甲状腺核医学

PRIMARY评分系统在PSMA PET检测临床显著性前列腺癌中的系统综述与荟萃分析

The PRIMARY Scoring System on PSMA PET for Clinically Significant Prostate Cancer Detection: A Systematic Review and Meta-Analysis.
PubMed 文献 · Clin Nucl Med · 2026-01-23

在活检初治队列中,PRIMARY≥3的合并敏感度为90%(95%CI:86%-93%),特异度为63%(95%CI:57%-69%)。结论认为PRIMARY具有高敏感度和中等特异度,与PI-RADS相当,阈值选择应反映临床意图。

要点

  • 活检初治患者中PRIMARY≥3检测csPCa的敏感度为90%,特异度为63%。
  • 阈值从≥3升至≥4,敏感度由89%降至81%,特异度由53%升至72%。
  • 三项头对头研究显示PRIMARY与PI-RADS诊断准确性相当。

核心结论

  • PRIMARY评分对临床显著性前列腺癌具有高敏感度和中等特异度,与PI-RADS相当。
  • 在活检初治男性中表现稳健,与mpMRI联合可进一步提高敏感度。
  • 阈值选择应反映临床意图,支持PRIMARY作为活检前风险分层和整合诊断流程的工具。

研究设计与样本

  • 主要分析聚焦活检初治患者;次要分析纳入所有研究而不论既往活检史,评估≥3与≥4阈值、比较PRIMARY与PI-RADS并考察联合效能。
  • 采用双变量随机效应模型估计合并敏感度和特异度。

主要发现

  • 活检初治队列(6项研究)中,PRIMARY≥3的合并敏感度为90%(95%CI:86%-93%),特异度为63%(95%CI:57%-69%)。
  • 扩展分析纳入9项研究而不论既往活检史,敏感度为87%(95%CI:82%-90%),特异度为56%(95%CI:46%-65%)。
  • 5项研究直接比较阈值,从≥3提高至≥4使敏感度从89%降至81%,特异度从53%升至72%。
  • 3项头对头研究显示PRIMARY与PI-RADS准确性相当。

关键数值与推荐

  • 活检初治患者中PRIMARY≥3:合并敏感度90%(95%CI:86%-93%),合并特异度63%(95%CI:57%-69%)。
  • 不论既往活检史的9项研究中PRIMARY:合并敏感度87%(95%CI:82%-90%),合并特异度56%(95%CI:46%-65%)。
  • 阈值≥3与≥4直接比较(5项研究):敏感度89%对81%,特异度53%对72%。

临床怎么用

  • PRIMARY可用于活检前风险分层,高敏感度支持其作为筛查工具减少csPCa漏诊。
  • 阈值选择应结合临床意图:≥3侧重敏感度,≥4侧重特异度。
  • 与mpMRI联合可进一步提高敏感度,支持整合诊断工作流。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE OF THE REPORT: The PRIMARY score standardizes interpretation of PSMA PET for intraprostatic assessment of clinically significant prostate cancer (csPCa). Although early studies are promising, no meta-analysis has systematically evaluated its accuracy. We aimed to assess the diagnostic performance of PRIMARY and compare it with PI-RADS. MATERIAL AND METHODS: A systematic review and meta-analysis were performed according to PRISMA-DTA guidelines. Studies assessing the PRIMARY score on PSMA PET/CT or PET/MRI for csPCa detection were included. The primary analysis focused on biopsy-naïve patients; secondary analyses incorporated all studies irrespective of prior histology, evaluated thresholds (≥3 vs. ≥4), compared PRIMARY with PI-RADS, and examined combined performance. Pooled sensitivity and specificity were estimated with a bivariate random-effects model. RESULTS: Thirteen studies (n=1974) were included. In biopsy-naïve cohorts (6 studies), PRIMARY ≥3 achieved pooled sensitivity/specificity of 90% (95% CI: 86%-93%) and 63% (95% CI: 57%-69%). In an expanded analysis of 9 studies regardless of prior biopsy, values were 87% (82%-90%) and 56% (46%-65%). Across 5 studies directly comparing thresholds, raising the cutoff from ≥3 to ≥4 reduced sensitivity from 89% to 81% but increased specificity from 53% to 72%. Three head-to-head studies showed comparable accuracy between PRIMARY and PI-RADS. CONCLUSIONS: PRIMARY demonstrates high sensitivity and moderate specificity for csPCa, comparable to PI-RADS. In biopsy-naïve men it shows robust performance, and combination with mpMRI further improves sensitivity. Threshold selection should reflect clinical intent, supporting PRIMARY as a tool for pre-biopsy risk stratification and integrated diagnostic workflows.

来源:Clin Nucl Med,查看原文。版权归原作者所有。

引用

  1. Mourato FA, Schmitt LG, Mariussi M, et al. The PRIMARY Scoring System on PSMA PET for Clinically Significant Prostate Cancer Detection: A Systematic Review and Meta-Analysis. Clin Nucl Med. 2026. PMID: 41631935. doi:10.1097/RLU.0000000000006309

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。